Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Massachusetts General Hospital · Dana-Farber Cancer Institute · +10 more institutions
Abstract
Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.
CAR+ T cells in the expansion phase. Patients had received at least three previous lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or were refractory to both drug classes. The primary end point was safety.
Citation impact
- FWCI
- 95.27
- Percentile
- 100%
- References
- 40
Authors
23- NRNoopur RajeCorresponding
Massachusetts General Hospital, Dana-Farber Cancer Institute
- JGJesús G. Berdeja
Sarah Cannon, Dana-Farber Cancer Institute, Tennessee Oncology
- YLYi Lin
Dana-Farber Cancer Institute, Mayo Clinic in Arizona
- DSDavid S. Siegel
Hackensack University Medical Center, Dana-Farber Cancer Institute
- SJSundar Jagannath
Mount Sinai Medical Center, Dana-Farber Cancer Institute
Topics & keywords
- Chimeric antigen receptor
- CAR T-cell therapy
- Multiple myeloma
- Cancer research
- Medicine
- Antigen
- Cell therapy
- Refractory (planetary science)
- Good health and well-being